Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:538837 vs VRTX, REGN, RVMD: Buyback Yield % Comparison
For the Biotechnology subindustry, Jeevan Scientific Technology's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jeevan Scientific Technology Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jeevan Scientific Technology's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Jeevan Scientific Technology's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jeevan Scientific Technology (BOM:538837) has a Buyback Yield % of -12.38 as of Aug. 09, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Jeevan Scientific Technology and its competitors. According to the industry distribution chart, Jeevan Scientific Technology ranks #403 out of 727 companies in the Biotechnology industry, placing it in the top 55.4%.
Is Jeevan Scientific Technology's Buyback Yield % too high?
Jeevan Scientific Technology's current Buyback Yield % is -12.38. Based on the distribution chart, Jeevan Scientific Technology ranks #403 out of 727 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jeevan Scientific Technology has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jeevan Scientific Technology's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jeevan Scientific Technology ranks #403 out of 727 companies for Buyback Yield %. This places Jeevan Scientific Technology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Jeevan Scientific Technology and its competitors. Jeevan Scientific Technology's current Buyback Yield % is -12.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jeevan Scientific Technology stock overvalued right now?
Based on GuruFocus' analysis, Jeevan Scientific Technology (BOM:538837) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹61.89, compared to a current price of ₹80.45 — trading 30% above its estimated fair value. The current Buyback Yield % is -12.38. Jeevan Scientific Technology's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Jeevan Scientific Technology (BOM:538837), the current Buyback Yield % is -12.38 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jeevan Scientific Technology (BOM:538837) Overvalued in 2026?
Based on GuruFocus' analysis, Jeevan Scientific Technology stock appears to be overvalued.
The current stock price of ₹80.45 is trading 30% above its estimated GF Value™ of ₹61.89.
GuruFocus considers Jeevan Scientific Technology to be Modestly Overvalued.
Key valuation signals for BOM:538837:
Buyback Yield %: -12.38
GF Value™: ₹61.89 vs. price of ₹80.45 (30% above fair value)
No single metric tells the full story. See the BOM:538837 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jeevan Scientific Technology Ltd is an India-based company engaged in providing clinical research and data management services. Jeevan Scientific is an independent clinical contract research organization, offering reliable, cost-effective, and technology-driven clinical research solutions to various clients across the globe. Its services offer high-value testing services, including bioanalytical services for small and large molecules, ranging across generics, biosimilars, and other new drugs. It operates in a single segment, namely clinical research services.
62GF Score
Get the complete analysis for BOM:538837
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:538837 has been successfully added to your 
